BRPI0911511A2 - formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo - Google Patents

formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo

Info

Publication number
BRPI0911511A2
BRPI0911511A2 BRPI0911511A BRPI0911511A BRPI0911511A2 BR PI0911511 A2 BRPI0911511 A2 BR PI0911511A2 BR PI0911511 A BRPI0911511 A BR PI0911511A BR PI0911511 A BRPI0911511 A BR PI0911511A BR PI0911511 A2 BRPI0911511 A2 BR PI0911511A2
Authority
BR
Brazil
Prior art keywords
lyophilized
formulation
dna
increase plasmid
expression
Prior art date
Application number
BRPI0911511A
Other languages
English (en)
Inventor
Jong-Mook Kim
Sujeong Kim
Wonsun Yoo
Woong Hahn
Original Assignee
Viromed Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Co Ltd filed Critical Viromed Co Ltd
Publication of BRPI0911511A2 publication Critical patent/BRPI0911511A2/pt
Publication of BRPI0911511B1 publication Critical patent/BRPI0911511B1/pt
Publication of BRPI0911511B8 publication Critical patent/BRPI0911511B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BRPI0911511A 2008-04-09 2009-04-09 formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo BRPI0911511B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4360508P 2008-04-09 2008-04-09
US61/043,605 2008-04-09
PCT/KR2009/001831 WO2009125986A2 (en) 2008-04-09 2009-04-09 Lyophilized dna formulations for enhanced expression of plasmid dna

Publications (3)

Publication Number Publication Date
BRPI0911511A2 true BRPI0911511A2 (pt) 2016-05-17
BRPI0911511B1 BRPI0911511B1 (pt) 2021-01-05
BRPI0911511B8 BRPI0911511B8 (pt) 2021-05-25

Family

ID=41162399

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911511A BRPI0911511B8 (pt) 2008-04-09 2009-04-09 formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo

Country Status (12)

Country Link
US (2) US20090258932A1 (pt)
EP (1) EP2281040B1 (pt)
JP (1) JP5579164B2 (pt)
KR (1) KR101290322B1 (pt)
CN (1) CN102046792B (pt)
AU (1) AU2009234598C1 (pt)
BR (1) BRPI0911511B8 (pt)
CA (1) CA2720611C (pt)
ES (1) ES2556711T3 (pt)
MX (1) MX2010010993A (pt)
RU (1) RU2470995C2 (pt)
WO (1) WO2009125986A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100562824B1 (ko) 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
ES2556711T3 (es) * 2008-04-09 2016-01-19 Viromed Co., Ltd. Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico
WO2011069529A1 (en) * 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
US9677078B2 (en) 2012-10-08 2017-06-13 Lipocalyx Gmbh Carboxylated polyamine derivatives as transfection reagents
AU2014337870B2 (en) 2013-10-22 2019-11-28 Helixmith Co., Ltd. Composition for preventing or treating amyotrophic lateral sclerosis using two or more isoforms of hepatocyte growth factor
US10435450B2 (en) 2015-01-21 2019-10-08 Centre National De La Recherche Scientifique MET receptor agonist proteins
CN106282227B (zh) * 2015-06-09 2022-02-08 北京诺思兰德生物技术股份有限公司 一种重组人肝细胞生长因子裸质粒的高密度发酵方法
JP7140353B2 (ja) * 2017-12-29 2022-09-22 ヘリックスミス カンパニー， リミテッド ハイブリッドｈｇｆ遺伝子が導入されたａａｖ（アデノ－関連ウイルス）ベクター
CA3106078A1 (en) 2018-07-17 2020-01-23 Junghun Lee Treatment of neuropathy with dna constructs expressing igf-1 isoforms
US11554179B2 (en) 2018-07-19 2023-01-17 Helixmith Co., Ltd Lyophilized pharmaceutical compositions for naked DNA gene therapy
CN110511926B (zh) * 2019-09-06 2021-11-30 郑州安图生物工程股份有限公司 一种质粒、假病毒的保存液及其用途
US20250205154A1 (en) * 2022-03-24 2025-06-26 Helixmith Co., Ltd Liquid formulation pharmaceutical composition comprising plasmid dna
WO2024059819A2 (en) 2022-09-15 2024-03-21 Tff Pharmaceuticals, Inc. Compositions of cannabinoids for delivery by inhalation

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
CA2022752C (en) * 1989-08-11 1998-07-07 Naomi Kitamura Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor
JP2634323B2 (ja) * 1990-07-13 1997-07-23 雪印乳業株式会社 Ｔｃｆ‐▲ｉｉ▼のアミノ酸配列をコードするｄｎａを含むプラスミド，形質転換細胞及びこれを用いて生理活性物質を生産する方法
US5661133B1 (en) * 1991-11-12 1999-06-01 Univ Michigan Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein
US7323297B1 (en) * 1992-04-03 2008-01-29 The Regents Of The University Of California Stabilized polynucleotide complexes and methods
US20030148968A1 (en) * 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US5869306A (en) * 1995-03-17 1999-02-09 Hisamitsu Pharmaceutical Co., Inc. Gene transfer preparation
AU707734B2 (en) * 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
JP3927248B2 (ja) * 1995-07-11 2007-06-06 第一製薬株式会社 Ｈｇｆ凍結乾燥製剤
EP0847757B1 (en) * 1995-08-29 2005-04-06 AnGes MG, Inc. Medicine comprising hgf gene
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
KR20070005030A (ko) 1997-05-06 2007-01-09 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 혈관형성성 트랜스유전자의 생체내 송달에 의한 심장 질환및 심실 리모델링을 치료하기 위한 방법 및 조성물
AU766238B2 (en) 1998-03-09 2003-10-09 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
EP1555033A3 (en) * 1998-03-13 2005-08-17 Wyeth Polynucleotide composition, method of preparation, and use thereof
ATE294594T1 (de) * 1998-03-13 2005-05-15 Wyeth Corp Polynukleotidzusammensetzung, verfahren zu deren herstellung und verwendung
US7276359B1 (en) * 1998-03-13 2007-10-02 Wyeth Polynucleotide composition, method of preparation, and use thereof
ES2313907T3 (es) * 1999-10-29 2009-03-16 Anges Mg, Inc. Terapia genica para la isquemia diabetica.
NZ546670A (en) 1999-11-05 2009-02-28 Univ California Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
DE60134021D1 (de) * 2000-06-27 2008-06-26 Anges Mg Inc Pharmazeutische zubereitungen zur angiogenese-therapie
US20030176347A1 (en) 2003-05-14 2003-09-18 Toshikazu Nakamura Remedies for amyotrophic lateral sclerosis
CN1150035C (zh) * 2000-12-21 2004-05-19 中国人民解放军军事医学科学院放射医学研究所 一种重组质粒及其在疾病防治中的应用
EP1234583A1 (en) * 2001-02-23 2002-08-28 F. Hoffmann-La Roche Ag PEG-conjugates of HGF-NK4
KR100562824B1 (ko) * 2002-03-20 2006-03-23 주식회사 바이로메드 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자
JP4917263B2 (ja) * 2002-12-23 2012-04-18 バイカル インコーポレイテッド 核酸／ブロックコポリマー／陽イオン性界面活性剤複合体を凍結乾燥する方法
KR101094032B1 (ko) * 2003-09-17 2011-12-19 센텔리옹 에스아에스 약학적 등급의 플라스미드 ｄｎａ의 제조 방법
US20050164208A1 (en) * 2004-01-22 2005-07-28 Paul Poulin Storage of genetic information
US20090130761A1 (en) 2006-05-17 2009-05-21 Yoshiyuki Koyama Freeze-Dried Product for Introducing Nucleic Acid, Oligonucleic Acid or Derivative Thereof
US20090202606A1 (en) * 2008-01-25 2009-08-13 Viromed Co., Ltd. Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
ES2556711T3 (es) 2008-04-09 2016-01-19 Viromed Co., Ltd. Formulaciones liofilizadas de ADN para el aumento de la expresión del ADN plasmídico

Also Published As

Publication number Publication date
BRPI0911511B1 (pt) 2021-01-05
AU2009234598B2 (en) 2011-07-14
WO2009125986A2 (en) 2009-10-15
EP2281040A2 (en) 2011-02-09
US8389492B2 (en) 2013-03-05
AU2009234598C1 (en) 2012-08-23
CA2720611A1 (en) 2009-10-15
EP2281040A4 (en) 2011-10-12
JP2011516545A (ja) 2011-05-26
JP5579164B2 (ja) 2014-08-27
CN102046792B (zh) 2014-12-10
AU2009234598A1 (en) 2009-10-15
BRPI0911511B8 (pt) 2021-05-25
RU2010145261A (ru) 2012-05-20
EP2281040B1 (en) 2015-11-25
US20110166211A1 (en) 2011-07-07
WO2009125986A3 (en) 2010-01-14
CA2720611C (en) 2016-07-12
US20090258932A1 (en) 2009-10-15
HK1155776A1 (zh) 2012-05-25
CN102046792A (zh) 2011-05-04
RU2470995C2 (ru) 2012-12-27
ES2556711T3 (es) 2016-01-19
KR20100129341A (ko) 2010-12-08
KR101290322B1 (ko) 2013-07-26
MX2010010993A (es) 2010-11-05

Similar Documents

Publication Publication Date Title
BRPI0911511A2 (pt) formulação de dna liofilizadas para aumentar a expressão de dna de plasmídeo
DK3018211T3 (da) Antisense-nukleinsyrer
LT3431076T (lt) Patobulinta lipidinė kompozicija
HUE041436T2 (hu) Tal-effektor-közvetített DNS-módosítás
BRPI0908968A2 (pt) Composição enriquecidas com hemicelulase para potencializar a hidrólise de biomassa
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BR112012001988A2 (pt) composição de insulina de ação prolongada
DK3097925T3 (da) Farmaceutisk sammensætning
DK2200646T3 (da) RNA-Vacciner
EP2504034A4 (en) Topical ibuprofen formulations
BRPI0917205A2 (pt) vacina polivalente
BRPI1004940A2 (pt) composição farmacêutica
BR112012012108A2 (pt) composição farmacêutica compreendendo propofol
BRPI0912026A2 (pt) formulação homeopática
HRP20181347T1 (hr) Formulacije dvoslojne tablete
BRPI0912106A2 (pt) probióticos para melhorar a microbiota intestinal
EP2488586A4 (en) HARDENING COMPOSITION
EP2495286A4 (en) HARDENING COMPOSITION
ES2397671T8 (es) Procedimiento para preparar voriconazol
BRPI1015939A2 (pt) composição farmacêutica
BRPI1007160A2 (pt) Método para esterilizar um material
BRPI1015147A2 (pt) métodos para melhorar a farmacocinética
BRPI1005919A2 (pt) composição imunogênica
EP2432794A4 (en) Trans-acting rna switches
BRPI1013383A2 (pt) Goma xantana aperfeiçoada

Legal Events

Date Code Title Description
B15I Others concerning applications: loss of priority
B12F Other appeals [chapter 12.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: HELIXMITH CO., LTD (KR)

B25G Requested change of headquarter approved

Owner name: HELIXMITH CO., LTD (KR)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09W Correction of the decision to grant [chapter 9.1.4 patent gazette]

Free format text: RETIFICACAO DO QUADRO 1

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF